Faeth Therapeutics

Q2 FY2026 EarningsQ2 FY26 net loss was $16.0M, significantly better than the consensus expectation of a $21.1M loss, while GAAP EPS of -$2.84 beat the mean estimate of -$4.76 due to lower-than-expected operating expenses and higher other income. The company reported zero revenue, in-line with expectations for a clinical-stage biotech. Following a $200M PIPE financing and merger, the cash position surged to $186.4M, providing substantial runway for the upcoming Phase 2 PIK-201 topline results in endometrial cancer expected by year-end.